good morning all... jane hopefully this call will help clear up any questions about imcl and cast a more positive light on things... i will not be able to listen in but if anyone does... please post a summary if you have a chance...
ImClone Investor Call for 9:00 AM EDT October 7, 1999
Business Wire - October 07, 1999 06:17
NEW YORK--(BW HealthWire)--Oct. 7, 1999--ImClone Systems Incorporated's (Nasdaq: IMCL) lead product candidate, C225, is an antibody antagonist to the Epidermal Growth Factor receptor that is currently in Phase III clinical trials for the treatment, in conjunction with radiation therapy or chemotherapy, of EGF receptor positive tumors. ImClone has become aware of a U.S. patent issued to a third party that includes claims relating to the potential use, subject to certain restrictions, of EGF receptor antibodies in conjunction with cytotoxic factors to inhibit tumor growth.
Outside patent counsel to the Company has reviewed the patent and has indicated that in such counsel's opinion, ImClone will be able to commercialize C225 upon FDA approval without infringing this third party patent.
To explain and clarify this issue ImClone will be conducting an investor conference call at 9:00 AM EDT at 1-800-510-0141 password 1405.
ImClone Systems Incorporated, headquartered in New York, is a biopharmaceutical company developing novel cancer therapeutic products including interventional therapeutics, cancer vaccines and blood cell growth factors for the treatment of cancer and cancer-related disorders.
CONTACT: ImClone Systems Incorporated
Andrea F. Rabney, 212/645-1405
Senior Director of Corporate Development
Investor Relations
or
Burns McClellan, Inc.
Jonathan M. Nugent (investors)
or Justin Jackson (media)
212/213-0006
|
